<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO> WSJ880412-0038 </DOCNO><HL> Business Brief: Syncor International Inc. </HL><SO> </SO><CO> SCOR ICN </CO><IN> TNM </IN><TEXT>   ICN Pharmaceuticals Inc., Costa Mesa, Calif., said it holds a 5.3% stake in Syncor International Corp.'s common shares outstanding.    In a filing with the Securities and Exchange Commission, ICN said it holds 568,000 Syncor common shares, including 48,500 shares purchased from March 16 to March 31 for $4.10 to $4.375 each.    Syncor closed yesterday in national over-the-counter trading at $5, unchanged.    A spokesman for Syncor, a Sylmar, Calif.-based maker and distributor of advanced medical diagnostic products, declined comment on the filing.    ICN last month sold its 8.6% stake in the voting stock of Swiss health-care giant F. Hoffmann-La Roche andamp; Co. for about $209 million, and said it would use the proceeds to &quot;acquire all or a part of one or more health-care companies.&quot;    Among the drugs that ICN and its various publicly traded units make and market is Virazole, which is being tested for use with AIDS patients. </TEXT></DOC>